Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
75 hedge funds and large institutions have $107M invested in Regulus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 8 closing their positions.
968% more call options, than puts
Call options by funds: $299K | Put options by funds: $28K
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
27% more capital invested
Capital invested by funds: $84.5M → $107M (+$22.4M)
9% more funds holding
Funds holding: 69 → 75 (+6)
0.67% more ownership
Funds ownership: 81.69% → 82.36% (+0.67%)
39% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.92M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.55M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.42M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.26M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$598K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.46M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.16M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.04M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$532K |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$279K |
RGLS Hedge Fund Activity: Q1 2025 in Review
75 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2025, worth a combined $107M — up 27% from $84.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new RGLS positions and 8 closed out — a net gain of 6 holders — while 17 added to existing stakes and 28 trimmed.
The largest buyer was Federated Hermes, adding an estimated $3.92M. The largest seller was Millennium Management, exiting entirely with an estimated $3.46M sold.
- 75 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2025, up from 69 in Q4 2024.
- Funds reported $107M of Regulus Therapeutics stock for Q1 2025, up 27% quarter-over-quarter.
- 14 funds opened new Regulus Therapeutics positions in Q1 2025 and 8 closed out, a net change of +6 holders.
- The largest Regulus Therapeutics buyer in Q1 2025 was Federated Hermes, an estimated $3.92M added.
- The largest Regulus Therapeutics seller in Q1 2025 was Millennium Management, an estimated $3.46M sold.
Based on aggregated 13F filings for Q1 2025.